These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 10357156)

  • 1. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
    Walenga JM; Jeske WP; Wallis DE; Bakhos M; Lewis BE; Leya F; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 1():77-81. PubMed ID: 10357156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
    von Segesser LK; Mueller X; Marty B; Horisberger J; Corno A
    Perfusion; 2001 Sep; 16(5):411-6. PubMed ID: 11565896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
    Cochran K; DeMartini TJ; Lewis BE; O Brien J; Steen LH; Grassman ED; Leya F
    J Invasive Cardiol; 2003 Nov; 15(11):617-21. PubMed ID: 14608129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome.
    Cruz-Gonzalez I; Sanchez-Ledesma M; Baron SJ; Healy JL; Watanabe H; Osakabe M; Yeh RW; Jang IK
    J Thromb Thrombolysis; 2008 Apr; 25(2):214-8. PubMed ID: 17632689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
    Lewis BE; Walenga JM; Wallis DE
    Semin Thromb Hemost; 1997; 23(2):197-202. PubMed ID: 9200347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
    Moriguchi A; Aoki T; Mihara K; Tojo N; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1094-101. PubMed ID: 14634048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
    Koster A; Meyer O; Fischer T; Kukucka M; Krabatsch T; Bauer M; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1254-5. PubMed ID: 11726910
    [No Abstract]   [Full Text] [Related]  

  • 10. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
    Durand M; Lecompte T; Hacquard M; Carteaux JP
    Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.
    Haas S; Walenga JM; Jeske WP; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 1():67-75. PubMed ID: 10357155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA; Ahmad S
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.
    Koster A; Loebe M; Mertzlufft F; Kuppe H; Hetzer R
    Ann Thorac Surg; 2000 Dec; 70(6):2160-1. PubMed ID: 11156147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
    Caputo RP; Giambartolomei A; Simons A; Reger M; Wagner S; Esente P
    J Invasive Cardiol; 2001 Sep; 13(9):657-60. PubMed ID: 11533507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety evaluation of tirofiban.
    Valgimigli M; Tebaldi M
    Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of GPIIb/IIIa platelet receptors].
    Chanu B
    Arch Mal Coeur Vaiss; 1999 Jul; 92(7):893-902. PubMed ID: 10443310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modern "antiplatelet agents" in unstable angina].
    Vahanian A; Garbarz E
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1521-6. PubMed ID: 9092413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.